Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer

Charles Blatti, Jesús de la Fuente, Huanyao Gao, Irene Marín-Goñi, Zikun Chen, Sihai D. Zhao, Winston Tan, Richard Weinshilboum, Krishna R. Kalari, Liewei Wang, Mikel Hernaez

Cancer Res (2023) 83 (8): 1361–1380.

https://doi.org/10.1158/0008-5472.CAN-22-1910

Published: 14 April 2023

View article titled, Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer

Includes: Supplementary data

Journal Articles

Abstract 1689: The role of circular RNAs in triple negative breast cancer and chemotherapy resistance

Xiyin Wang, Michael J. Emch, Xiaojia Tang, Jia Yu, Krishna R. Kalari, Liewei Wang, Matthew P. Goetz, John R. Hawse

Cancer Res (2023) 83 (7_Supplement): 1689.

https://doi.org/10.1158/1538-7445.AM2023-1689

Published: 04 April 2023

View article titled, Abstract 1689: The role of circular RNAs in triple negative breast cancer and chemotherapy resistance

Journal Articles

Abstract 4290: ReCorDE: A novel computational framework to discover potential combinations of anti-cancer drugs

Emily T. Ghose, August John, Huanyao Gao, Krishna R. Kalari, Liewei Wang

Cancer Res (2023) 83 (7_Supplement): 4290.

https://doi.org/10.1158/1538-7445.AM2023-4290

Published: 04 April 2023

View article titled, Abstract 4290: ReCorDE: A novel computational framework to discover potential combinations of anti-cancer drugs

Journal Articles

Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial

Tufia C. Haddad, Vera Suman, Karthik V. Giridhar, Alvaro Moreno-Aspitia, Donald Northfelt, Brenda Ernst, Kostandinos Sideras, Ciara C. O’Sullivan, Ravinder Singh, Zeruesenay Desta, Jodi Taraba, Barbara Goodnature, Matthew P. Goetz, Liewei Wang, James N. Ingle

Cancer Res (2023) 83 (5_Supplement): OT1-04-02.

https://doi.org/10.1158/1538-7445.SABCS22-OT1-04-02

Published: 01 March 2023

View article titled, Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial

Journal Articles

Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer

Lixuan Wei, Huanyao Gao, Jia Yu, Huan Zhang, Thanh Thanh L. Nguyen, Yayun Gu, Marie R. Passow, Jodi M. Carter, Bo Qin, Judy C. Boughey, Matthew P. Goetz, Richard M. Weinshilboum, James N. Ingle, Liewei Wang

Cancer Res (2023) 83 (3): 456–470.

https://doi.org/10.1158/0008-5472.CAN-22-1016

Published: 03 February 2023

View article titled, Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract PD1-03: Estrogen receptor is a target of enzalutamide in ER+ breast cancer

Lixuan Wei, Jia Yu, Huanyao Gao, Huan Zhang, Thanh Nguyen, Yayun Gu, Richard M. Weinshilboum, James N. Ingle, Liewei Wang

Cancer Res (2022) 82 (4_Supplement): PD1-03.

https://doi.org/10.1158/1538-7445.SABCS21-PD1-03

Published: 15 February 2022

View article titled, Abstract PD1-03: Estrogen receptor is a target of enzalutamide in ER+ breast cancer

Journal Articles

Abstract OT2-19-05: A phase I/II trial of abemaciclib and T-DM1 in women and men with HER2-positive advanced or metastatic breast cancer that has progressed on treatment with a taxane, trastuzumab and pertuzumab (THP) (ACCRU-BR-1801)

Cancer Res (2022) 82 (4_Supplement): OT2-19-05.

https://doi.org/10.1158/1538-7445.SABCS21-OT2-19-05

Published: 15 February 2022

View article titled, Abstract OT2-19-05: A phase I/II trial of abemaciclib and T-DM1 in women and men with HER2-positive advanced or metastatic breast cancer that has progressed on treatment with a taxane, trastuzumab and pertuzumab (THP) (ACCRU-BR-1801)

Journal Articles

Abstract P5-01-07: Patient-derived xenografts (PDXs) generated from hormone receptor-positive breast cancer (BC) before and after cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) treatment: Initial findings from the PROMISE study

Cancer Res (2022) 82 (4_Supplement): P5-01-07.

https://doi.org/10.1158/1538-7445.SABCS21-P5-01-07

Published: 15 February 2022

View article titled, Abstract P5-01-07: Patient-derived xenografts (PDXs) generated from hormone receptor-positive breast cancer (BC) before and after cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) treatment: Initial findings from the PROMISE study

Journal Articles

Abstract P5-13-22: Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)

Cancer Res (2022) 82 (4_Supplement): P5-13-22.

https://doi.org/10.1158/1538-7445.SABCS21-P5-13-22

Published: 15 February 2022

View article titled, Abstract P5-13-22: Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)

Journal Articles

Abstract P4-01-05: Multi-omics data shows downregulation of mismatch repair, purin and tublin pathways in AR-negative triple-negative chemotherapy-resistant tumors

Krishna R Kalari, Vera J Suman, Xiaojia Tang, Jason P Sinnwell, Kevin J Thompson, Peter T Vedell, Jodi M Carter, Sarah A McLaughlin, Alvaro Moreno Aspitia, Donald W Northfelt, Richard J Gray, Richard Weinshilboum, Liewei Wang, Judy C Boughey, Matthew Goetz

Cancer Res (2022) 82 (4_Supplement): P4-01-05.

https://doi.org/10.1158/1538-7445.SABCS21-P4-01-05

Published: 15 February 2022

View article titled, Abstract P4-01-05: Multi-omics data shows downregulation of mismatch repair, purin and tublin pathways in AR-negative triple-negative chemotherapy-resistant tumors

Journal Articles

Abstract P4-01-03: Multiomics data reveal novel biomarkers for CDK4/6 resistance

Cancer Res (2022) 82 (4_Supplement): P4-01-03.

https://doi.org/10.1158/1538-7445.SABCS21-P4-01-03

Published: 15 February 2022

View article titled, Abstract P4-01-03: Multiomics data reveal novel biomarkers for CDK4/6 resistance

Journal Articles

Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks

Ishwar N. Kohale, Danielle M. Burgenske, Ann C. Mladek, Katrina K. Bakken, Jenevieve Kuang, Judy C. Boughey, Liewei Wang, Jodi M. Carter, Eric B. Haura, Matthew P. Goetz, Jann N. Sarkaria, Forest M. White

Cancer Res (2021) 81 (14): 3930–3941.

https://doi.org/10.1158/0008-5472.CAN-21-0214

Published: 15 July 2021

View article titled, Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks

Includes: Supplementary data

Journal Articles

Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

Qin Zhou, Michelle E. Howard, Xinyi Tu, Qian Zhu, Janet M. Denbeigh, Nicholas B. Remmes, Michael G. Herman, Chris J. Beltran, Jian Yuan, Patricia T. Greipp, Judy C. Boughey, Liewei Wang, Neil Johnson, Matthew P. Goetz, Jann N. Sarkaria, Zhenkun Lou, Robert W. Mutter

Cancer Res (2021) 81 (12): 3333–3346.

https://doi.org/10.1158/0008-5472.CAN-20-2960

Published: 15 June 2021

View article titled, Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

Includes: Supplementary data

Journal Articles

Abstract PD7-05: Neoadjuvant chemotherapy selectively alters spatially-defined immune landscapes in clinical luminal B HR+/HER2- breast cancers: Analysis of the breast cancer genome guided therapy study (BEAUTY)

Jodi M Carter, Judy C Boughey, Jun He, Vera J Suman, Xue Wang, Jennifer M Kachergus, Krishna R Kalari, Liewei Wang, Richard Weinshilboum, Ann M Moyer, Sarah A McLaughlin, Alvaro Moreno-Aspitia, Donald W Northfelt, Richard J Gray, James N Ingle, E. Aubrey Thompson, Matthew P Goetz

Cancer Res (2021) 81 (4_Supplement): PD7-05.

https://doi.org/10.1158/1538-7445.SABCS20-PD7-05

Published: 15 February 2021

View article titled, Abstract PD7-05: Neoadjuvant chemotherapy selectively alters spatially-defined immune landscapes in clinical luminal B HR+/HER2- breast cancers: Analysis of the breast cancer genome guided therapy study (BEAUTY)

Journal Articles

Abstract PD7-04: Association between patient derived xenograft (PDX) take rate and breast cancer recurrence in the prospective breast cancer genome guided therapy study (BEAUTY)

Judy C. Boughey, Vera J. Suman, Jia Yu, Katelyn Santo, Jason P. Sinnwell, Jodi M. Carter, Krishna R. Kalari, Xiaojia Tang, Sarah A. McLaughlin, Alvaro Moreno Aspitia, John A. Copland, III, Donald W. Northfelt, Richard J. Gray, Katie N. Hunt, Amy Lynn Conners, Richard Weinshilboum, Liewei Wang, Matthew P. Goetz

Cancer Res (2021) 81 (4_Supplement): PD7-04.

https://doi.org/10.1158/1538-7445.SABCS20-PD7-04

Published: 15 February 2021

View article titled, Abstract PD7-04: Association between patient derived xenograft (PDX) take rate and breast cancer recurrence in the prospective breast cancer genome guided therapy study (BEAUTY)

Journal Articles

Abstract PD8-04: Antitumor activity of Z-endoxifen (ENDX) is mediated via PKCβ1-dependent ERα loss and cell cycle arrest in ERα-positive breast cancer

Swaathi Jayaraman, Mary J Kuffel, Krishna R Kalari, Kevin J Thompson, Xiaojia Tang, Vera J Suman, Elizabeth S Bruinsma, Ciara C O'Sullivan, Liewei Wang, Richard Weinshilboum, James N Ingle, John R Hawse, Matthew P Goetz

Cancer Res (2021) 81 (4_Supplement): PD8-04.

https://doi.org/10.1158/1538-7445.SABCS20-PD8-04

Published: 15 February 2021

View article titled, Abstract PD8-04: Antitumor activity of Z-endoxifen (ENDX) is mediated via PKCβ1-dependent ERα loss and cell cycle arrest in ERα-positive breast cancer

Journal Articles

Abstract PS5-24: Novel genomic variants and pathways associated with baseline serum thymidine kinase 1 levels in HR-positive HER2-negative MBC patients commencing palbociclib and letrozole

Cancer Res (2021) 81 (4_Supplement): PS5-24.

https://doi.org/10.1158/1538-7445.SABCS20-PS5-24

Published: 15 February 2021

View article titled, Abstract PS5-24: Novel genomic variants and pathways associated with baseline serum thymidine kinase 1 levels in HR-positive HER2-negative MBC patients commencing palbociclib and letrozole

Journal Articles

Abstract PS5-36: Computational modeling of androgen receptor (AR) and estrogen receptor as predictive biomarkers of response to AR agonists and antagonists

Lixuan Wei, Huanyao Gao, Jia Yu, Duan Liu, Huan Zhang, Thanh Nguyen, Marie R Passow, Jodi M Carter, Richard M Weinshilboum, James N Ingle, Liewei Wang

Cancer Res (2021) 81 (4_Supplement): PS5-36.

https://doi.org/10.1158/1538-7445.SABCS20-PS5-36

Published: 15 February 2021

View article titled, Abstract PS5-36: Computational modeling of androgen receptor (AR) and estrogen receptor as predictive biomarkers of response to AR agonists and antagonists

Journal Articles

Abstract LB-103: The interaction between SNP genotype and aromatase inhibitor treatment response in early breast cancer

Junmei Cairns, James N. Ingle, Krishna R. Kalari, Lois E. Shepherd, Matthew J. Ellis, Paul E. Goss, Poulami Barman, Erin E. Carlson, Matthew P. Goetz, Richard M. Weinshilboum, Liewei Wang

Cancer Res (2020) 80 (16_Supplement): LB-103.

https://doi.org/10.1158/1538-7445.AM2020-LB-103

Published: 15 August 2020

View article titled, Abstract LB-103: The interaction between SNP genotype and aromatase inhibitor treatment response in early breast cancer

Journal Articles

Abstract 1928: Study of copy number amplification and chemo-response in triple negative breast cancer

Jordan Mark Grainger, Jia Yu, Krishna R. Kalari, Peter Vedell, Kevin Thompson, Matthew P. Goetz, Vera J. Suman, Judy C. Boughey, Liewei Wang

Cancer Res (2020) 80 (16_Supplement): 1928.

https://doi.org/10.1158/1538-7445.AM2020-1928

Published: 15 August 2020

View article titled, Abstract 1928: Study of copy number amplification and chemo-response in triple negative breast cancer

NARROW

Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer

Abstract 1689: The role of circular RNAs in triple negative breast cancer and chemotherapy resistance

Abstract 4290: ReCorDE: A novel computational framework to discover potential combinations of anti-cancer drugs

Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial

Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer

Abstract PD1-03: Estrogen receptor is a target of enzalutamide in ER+ breast cancer

Abstract OT2-19-05: A phase I/II trial of abemaciclib and T-DM1 in women and men with HER2-positive advanced or metastatic breast cancer that has progressed on treatment with a taxane, trastuzumab and pertuzumab (THP) (ACCRU-BR-1801)

Abstract P5-01-07: Patient-derived xenografts (PDXs) generated from hormone receptor-positive breast cancer (BC) before and after cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) treatment: Initial findings from the PROMISE study

Abstract P5-13-22: Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)

Abstract P4-01-05: Multi-omics data shows downregulation of mismatch repair, purin and tublin pathways in AR-negative triple-negative chemotherapy-resistant tumors

Abstract P4-01-03: Multiomics data reveal novel biomarkers for CDK4/6 resistance

Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks

Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining

Abstract PD7-05: Neoadjuvant chemotherapy selectively alters spatially-defined immune landscapes in clinical luminal B HR+/HER2- breast cancers: Analysis of the breast cancer genome guided therapy study (BEAUTY)

Abstract PD7-04: Association between patient derived xenograft (PDX) take rate and breast cancer recurrence in the prospective breast cancer genome guided therapy study (BEAUTY)

Abstract PD8-04: Antitumor activity of Z-endoxifen (ENDX) is mediated via PKCβ1-dependent ERα loss and cell cycle arrest in ERα-positive breast cancer

Abstract PS5-24: Novel genomic variants and pathways associated with baseline serum thymidine kinase 1 levels in HR-positive HER2-negative MBC patients commencing palbociclib and letrozole

Abstract PS5-36: Computational modeling of androgen receptor (AR) and estrogen receptor as predictive biomarkers of response to AR agonists and antagonists

Abstract LB-103: The interaction between SNP genotype and aromatase inhibitor treatment response in early breast cancer

Abstract 1928: Study of copy number amplification and chemo-response in triple negative breast cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only